Paul Krzyzanowski
Paul is a computational biologist and writer living in Toronto. He's been a contributor to Signals for three years, writing articles for the general public about how biotechnology and biomedical research can be used to solve pressing medical problems.
Alongside Paul's experience in computational biology,
bioinformatics,
and molecular genetics, he's interested in how academic research develops into real world, commercial technology, and what's needed for the Canadian biotech industry needs to grow.
Paul is currently a Post-doctoral Fellow at the Ontario Institute of Cancer Research. Prior to joining the OICR, he worked at the Ottawa Hospital Research
Institute and earned a Ph.D. from the University of Ottawa, specializing in computational biology. And finally, Paul earned an H.B.Sc. from the University of Toronto a long time ago.
Paul's blog can be read at www.checkmatescientist.net
Posts by: Paul
– Nature kicked off 2013 with an unsettling article about how privileged information from research studies is being used to garner gigantic returns for investors, large and small. It’s not surprising, considering that one of the most egregious cases of so called academic information being used for insider trading of stock in public companies, Elan […]
This year, your household will pay $360 for the use of Intellectual Property (IP) held by people and corporations outside of Canada. For a little less than a dollar a day, you’re supporting industries like biotechnology, high-tech electronics, and engineering in other countries. Two policy think-tanks believe it’s time for Canadians to flip that balance […]
While the 2012 US election was in full swing, I reminded readers that despite the dominance of the world’s economic problems in this cycle, stem cell research was a political issue that hadn’t completely gone away.[pullquote]Ironically, if – and this is a big IF – the iPS work plays out, every cell in our […]
[pullquote]How will Romney’s opinion change in light of papers, which describe healthy mice being created from iPS cells?[/pullquote]As 2012 slowly creeps on we can finally see November’s Presidential Election in the United States on the horizon marking the end of a nineteen month-long election process, which feels like an eternity compared to Canada’s last election, which lasted all of 38 […]
Faced with patent shortages to replace flagship products, Big Pharma is increasing investments in smaller biotech companies to capture innovations early. Most new companies wither and die if they run out of initial funds before they’re profitable. In biotech, companies may strive to hit goals such as proving that a technology works as intended, developing […]
High stakes: Unpublished research brings big profits and huge losses – to insider traders
– Nature kicked off 2013 with an unsettling article about how privileged information from research studies is being used to garner gigantic returns for investors, large and small. It’s not surprising, considering that one of the most egregious cases of so called academic information being used for insider trading of stock in public companies, Elan […]